Ocular Therapeutix (OCUL) Reports First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for Treatment of Dry Eye Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Ocular Therapeutix (OCUL) Reports First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for Treatment of Dry Eye Disease
(NASDAQ: OCUL) Delayed: 9.99 -0.15 (1.48%)
Previous Close $10.14    52 Week High $14.50 
Open $10.15    52 Week Low $4.04 
Day High $10.26    P/E N/A 
Day Low $9.90    EPS $0.00 
Volume 4,100,928